Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

Cell(2023)10.1016/j.cell.2023.08.041Source: DataRank Database

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells is a research paper published in Cell (2023). On theSindex it has a DataRank of 3.4. It has been cited 190 times, with 100 citing works in its 1-hop citation network.

N/A

3.4DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access190 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

geo gen nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT03399448

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (29 grants)OA: hybridTopics (52)IDs (PubMed, PMC)Annotations (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 23%Citation Network 77%

Base Score Contribution

0.788

From this paper's citation signal

Citation Network Contribution

2.6

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Overcoming TGFβ and activin A suppression boosts NK cell antitumor function
Nature Immunology20252 citations5 referencesContributes 0.220
Heparin Specifically Inhibits CRISPR/Cas12 Activation, Enabling Ultrasensitive Heparin Detection and Gene Editing Regulation
Analytical Chemistry202429 citations37 referencesContributes 0.092
Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale genomic alterations
Nature Biotechnology202471 citations48 referencesContributes 0.089
Unbiased assessment of genome integrity and purging of adverse outcomes at the target locus upon editing of CD4+ T‐cells for the treatment of Hyper IgM1
The EMBO Journal202310 citations34 referencesContributes 0.071
Triple knockdown of CD11a , CD49d , and PSGL1 in T cells reduces CAR-T cell toxicity but preserves activity against solid tumors in mice
Science Translational Medicine202514 citations41 referencesContributes 0.066

Authors (23)

Nadav Brandes ORCID,Raymund Bueno ORCID,Marena Trinidad ORCID,Thomas Mazumder ORCID,Bingfei Yu ORCID

Live enrichment

PubMed:37794590 PMC:PMC10664023

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Grant: R01AR071522

Cancer Research Institute

Grant: CRI4499

National Heart, Lung, and Blood Institute

Grant: F31HL156468-01

California Institute for Regenerative Medicine

Grant: DISC2-13212

National Cancer Institute

Grant: R35CA209919

National Cancer Institute

Grant: RM1HG007735

National Cancer Institute

Grant: RM1HG009490

National Institute of General Medical Sciences

Grant: R01-GM065050

National Institute of Allergy and Infectious Diseases

Grant: R01AI136972

National Institute of Allergy and Infectious Diseases

Grant: U01AI142817-02

NHLBI NIH HHS

Grant: F31 HL156468

NHGRI NIH HHS

Grant: R01 HG011239

NIGMS NIH HHS

Grant: T32 GM067547

NIGMS NIH HHS

Grant: R01 GM065050

NIAID NIH HHS

Grant: U01 AI142817

National Institutes of Health

Grant: 2RM1HG009490-06

Center for Genomic Editing and Recording: Development and Application of Next-Generation Genome and Epigenome Editing Methods to Advance the Study and Treatment of Human Disease

National Institutes of Health

Grant: 5R01GM065050-15

Atomic-Resolution Analysis of Translation Control

National Institutes of Health

Grant: 5R01AR071522-04

Fine mapping rheumatic disease variants using functional genomic sequencing

National Institutes of Health

Grant: 5RM1HG007735-08

Center for Personal Dynamic Regulomes

National Institutes of Health

Grant: 5R01AI136972-03

Genetic regulation and immunological function of ERAP2 haplotypes

National Institutes of Health

Grant: 5R35CA209919-02

LncRNA mechanisms in cancer

National Institutes of Health

Grant: 5F31HL156468-02

Characterization and engineering of a compact genome editor for adeno-associated virus delivery to correct mutations causing cystic fibrosis

National Institutes of Health

Grant: 5U01AI142817-04

Expanding CRISPR-Cas editing technology through exploration of novel Cas proteins and DNA repair systems

Parker Institute for Cancer Immunotherapy

V Foundation for Cancer Research

Universiteit Utrecht

Howard Hughes Medical Institute

National Institutes of Health

Howard Hughes Medical Institute

hybridLicense: cc-by

publisherhttp://www.cell.com/article/S0092867423009753/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0092867423009753?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0092867423009753?httpAccept=text/plain

repositoryhttps://escholarship.org/content/qt4111p9q6/qt4111p9q6.pdf?t=s513id

repositoryhttps://www.osti.gov/servlets/purl/2470653

Fields of Study

HumansChromosomesCRISPR-Cas SystemsDNA DamageGene EditingT-LymphocytesClinical Trials as TopicChromosome Aberrations

MeSH Terms

T-LymphocytesChromosomesHumansDNA DamageChromosome AberrationsClinical Trials as TopicCRISPR-Cas SystemsGene Editing

Keywords

DNA repairT cellsAneuploidyClinical TrialChromosome LossGenome EditingCrispr-cas9ImmunoengineeringCrispr ScreenCar T cellsT-LymphocytesImmunology610BioengineeringMedical and Health SciencesArticleChromosomesClinical ResearchGeneticsHumansCancerGene EditingChromosome AberrationsCAR T cellsClinical Trials as TopicBiomedical and Clinical Sciences5.2 Cellular and gene therapiesGene TherapyBiological Sciences5.1 Pharmaceuticalsgenome editing&#x3aGeneric health relevanceCRISPR-Cas SystemsBiotechnologyDevelopmental BiologyDNA Damage